Abbott Price Prediction: Where Will the Stock Be in 2027
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) has pulled back sharply in 2026. Our Wall St. price target for Abbott is $125.10, representing 24.24% upside from the current price of $100.69. Our recommendation is buy, with a high (90%)…
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) has pulled back sharply in 2026. Our Wall St. price target for Abbott is $125.10, representing 24.24% upside from the current price of $100.69. Our recommendation is buy, with a high (90%) confidence level.
| Metric | Value |
|---|---|
| Current Price | $100.69 |
| 24/7 Wall St. Price Target | $125.10 |
| Upside | +24.24% |
| Recommendation | BUY |
| Confidence Level | 90% |
Abbott trades near its 52-week low of $99.06, well below the $137.13 52-week high. Q1 2026 earnings arrive in two days.
A Tough Stretch for Shareholders
Abbott shares have declined 19.22% year-to-date and 6.79% over the past month. The stock sits well below its 52-week high and trades beneath both its 50-day moving average of $108.92 and 200-day moving average of $123.50.
In Q4 2025, Abbott reported adjusted diluted EPS of $1.50, beating the $1.49 estimate. Revenue of $11.459B missed the $11.806B consensus, but gross profit rose 9.24% year-over-year and operating income climbed 13.12%. T
he net income figure of -80.76% YoY reflects a one-time $165M legal settlement charge, with underlying operations remaining intact. Full-year 2025 adjusted EPS of $5.15 demonstrated solid execution.
The Bull Case
FreeStyle Libre drives the bull thesis. CGM sales hit $2B in Q4 2025, up 15% YoY, running at 15-21% growth rates throughout 2025. Retail expansion and obesity drug tailwinds (GLP-1 patients still need glucose monitoring) could sustain that growth into 2027.
The $21 billion Exact Sciences acquisition, expected to close in Q2 2026, adds cancer diagnostics and broadens Abbott’s addressable market. Management guided for 6.5%-7.5% organic sales growth and $5.55-$5.80 adjusted EPS in 2026, roughly 10% growth at the midpoint.
The bull case scenario reaches $144.63. Analyst consensus target of $131.44 with 22 buy ratings and zero sells underscores Street confidence.
What Could Go Wrong
The bear case lands at $114.39. Key risks include Diagnostics pressure from COVID-19 testing collapse (from $265M to $69M YoY in Q3 2025), China volume-based procurement headwinds, and Nutrition softness with -8.9% revenue in Q4 2025.
Foreign exchange was a 2.8 percentage point drag in Q1 2025 and tariff uncertainty adds macro risk. Exact Sciences integration carries execution risk at $21 billion. The Nutrition decline reflects deliberate pricing strategy, with new product launches planned for 2026. Abbott’s forward P/E of 18x is reasonable for a company with this growth profile and dividend pedigree.
The Verdict
The 24/7 Wall St. price target of $125.10 implies meaningful recovery from 52-week low. Our buy recommendation carries 90% confidence. FreeStyle Libre momentum, FDA-approved devices in the pipeline, a 54-year dividend growth streak, and aggressive insider buying tip the scale.
Investors should weigh Q1 2026 earnings results and whether organic growth is confirmed, as well as the Exact Sciences deal closing timeline. CGM growth trajectory and Diagnostics performance beyond COVID normalization remain key metrics to monitor. At $100.69, the market prices in the risks. Our model says the reward is greater.
Abbott Price Projection 2026-2030
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $110.71 |
| 2027 | $125.10 |
| 2028 | $137.61 |
| 2029 | $149.99 |
| 2030 | $161.99 |
These projections assume Abbott executes on CGM growth, successfully integrates Exact Sciences, and sustains margin expansion. Upside could result from faster FreeStyle Libre penetration or electrophysiology breakthroughs. Downside centers on macro headwinds, tariffs, or integration missteps.
Contact [email protected] for any questions or corrections.
Vandita Jadeja is a financial publisher with over a decade of experience writing about financial topics, including investment, savings, retirement, insurance and banking. Vandita is a Chartered Accountant who loves to debunk financial concepts for readers.
Her work has appeared on sites that include The Motley Fool, InvestorPlace, and Benzinga. She covers investing and focuses on stock picks and price prediction for 24/7 Wall St.
When not looking for the next stock investment opportunity, she can be found traveling, reading, chasing sunsets and enjoying her iced latte.
